| Insiders | Shares | % | Avg Price | Total $ | |
|---|---|---|---|---|---|
| Buys | 0 | ||||
| Sells | 1 | -7.2K | 100% | $16.33 | -$118K |
| Net | -1 | -7.2K | -100% | -$118K |
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Report Date |
|---|---|---|---|---|---|
| Johnson & Johnson | 10%+ Owner | $33.7M | Apr 9, 2024 | ||
| Versant Venture Capital VI, L.P. | 10%+ Owner | $8.93M | Apr 9, 2024 | ||
| Daniel S. Lorrain | Chief Scientific Officer | $2.76M | -$118K | -4.08% | Nov 25, 2024 |
| Stephen L. Huhn | CMO & Sr VP, Clinical Dev. | $218K | Aug 13, 2024 | ||
| Carmine N. Stengone | CEO and President, Director | $198K | May 24, 2024 | ||
| Olivia C. Ware | Director | May 24, 2024 | |||
| Troy A. Ignelzi | Director | May 24, 2024 | |||
| John Stephen Healy | General Counsel and Corp Sec | Jun 3, 2024 | |||
| Sarah Boyce | Director | Jun 24, 2024 | |||
| Peter Slover | Chief Financial Officer | May 24, 2024 | |||
| Todd R. Brady | Director | May 24, 2024 | |||
| Lori Lyons-Williams | Director | May 24, 2024 | |||
| Evert B. Schimmelpennink | Director | May 24, 2024 |
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|